Literature DB >> 25123534

Post mortem concentrations of endogenous gamma hydroxybutyric acid (GHB) and in vitro formation in stored blood and urine samples.

Francesco Paolo Busardò1, Elisabetta Bertol2, Fabio Vaiano2, Giovanni Baglio3, Angelo Montana4, Nunziata Barbera4, Simona Zaami5, Guido Romano4.   

Abstract

Gamma-hydroxybutyrate (GHB) is a central nervous system depressant, primarily used as a recreational drug of abuse with numerous names. It has also been involved in various instances of drug-facilitated sexual assault due to its potential incapacitating effects. The first aim of this paper is to measure the post-mortem concentration of endogenous GHB in whole blood and urine samples of 30 GHB free-users, who have been divided according to the post-mortem interval (PMI) in three groups (first group: 24-36h; second group: 37-72h; third group: 73-192h), trying to evaluate the role of PMI in affecting post mortem levels. Second, the Authors have evaluated the new formation of GHB in vitro in blood and urine samples of the three groups, which have been stored at -20°C, 4°C and 20°C over a period of one month. The concentrations were measured by GC-MS after liquid-liquid extraction according to the method validated and published by Elliot (For. Sci. Int., 2003). For urine samples, GHB concentrations were creatinine-normalized. In the first group the GHB mean concentration measured after autopsy was: 2.14mg/L (range 0.54-3.21mg/L) in blood and 3.90mg/g (range 0.60-4.81mg/g) in urine; in the second group it was: 5.13mg/L (range 1.11-9.60mg/L) in blood and 3.93mg/g (range 0.91-7.25mg/g) in urine; in the third group it was: 11.8mg/L (range 3.95-24.12mg/L) in blood and 9.83mg/g (range 3.67-21.90mg/g) in urine. The results obtained in blood and urine samples showed a statistically significant difference among groups (p<0.001) in the first analysis performed immediately after autopsy. Throughout the period of investigation up to 4 weeks, the comparison of storage temperatures within each group showed in blood and urine samples a mean difference at 20°C compared to -20°C not statistically significant at the 10% level. These findings allow us to affirm that the PMI strongly affects the post mortem production of GHB in blood and urine samples. Regarding the new formation of GHB in vitro both in blood and urine samples of the three groups, which have been stored at -20°C, 4°C and 20°C over a period of one month, although there was no significant increases of GHB levels throughout the period of investigation, the lowest increases were found both in blood and urine at -20°C, therefore we recommend the latter as optimal storage temperature.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Endogenous concentrations; Gamma hydroxybutyric acid (GHB); Stored blood and urine samples, In vitro formation

Mesh:

Substances:

Year:  2014        PMID: 25123534     DOI: 10.1016/j.forsciint.2014.07.019

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  10 in total

1.  The challenge of post-mortem GHB analysis: storage conditions and specimen types are both important.

Authors:  J Kietzerow; B Otto; N Wilke; H Rohde; S Iwersen-Bergmann; H Andresen-Streichert
Journal:  Int J Legal Med       Date:  2019-10-09       Impact factor: 2.686

2.  Comparison of endogenous GHB concentrations in blood and hair in death cases with emphasis on the post mortem interval.

Authors:  André L Castro; Sónia Tarelho; Mário Dias; Flávio Reis; Helena M Teixeira
Journal:  Int J Legal Med       Date:  2016-02-04       Impact factor: 2.686

Review 3.  Anabolic Androgenic Steroid (AAS) related deaths: autoptic, histopathological and toxicological findings.

Authors:  Paola Frati; Francesco P Busardò; Luigi Cipolloni; Enrico De Dominicis; Vittorio Fineschi
Journal:  Curr Neuropharmacol       Date:  2015-01       Impact factor: 7.363

Review 4.  GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome.

Authors:  Francesco P Busardò; Alan W Jones
Journal:  Curr Neuropharmacol       Date:  2015-01       Impact factor: 7.363

5.  Gamma-hydroxybutyrate and keratinocytes proliferation (correspondence to Int J Crit Illn Inj Sci 2014;2:108-13).

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  Int J Crit Illn Inj Sci       Date:  2016 Jan-Mar

6.  Sudden cardiac death in anabolic androgenic steroids abuse: case report and literature review.

Authors:  Ana Isabel Hernández-Guerra; Javier Tapia; Luis Manuel Menéndez-Quintanal; Joaquín S Lucena
Journal:  Forensic Sci Res       Date:  2019-08-19

7.  Toxicological screening in the Amsterdam acute setting becomes more relevant if the standard panel of the drugs-of-abuse point-of-care test is expanded with GHB and ketamine.

Authors:  J A J van der Schaar; M E Attema-de Jonge; F M J Gresnigt; E J F Franssen
Journal:  Toxicol Rep       Date:  2020-04-20

Review 8.  Gamma-hydroxybutyrate abuse: pharmacology and poisoning and withdrawal management.

Authors:  Enrico Marinelli; Renata Beck; Antonio Malvasi; Alfredo Fabrizio Lo Faro; Simona Zaami
Journal:  Arh Hig Rada Toksikol       Date:  2020-03-01       Impact factor: 1.948

9.  A Forensic Diagnostic Algorithm for Drug-Related Deaths: A Case Series.

Authors:  Antonina Argo; Stefania Zerbo; Roberto Buscemi; Claudia Trignano; Elisabetta Bertol; Giuseppe Davide Albano; Fabio Vaiano
Journal:  Toxics       Date:  2022-03-22

10.  Has GBL replaced GHB in recreational settings?

Authors:  Anastasio Tini; Alessandro Del Rio
Journal:  Arh Hig Rada Toksikol       Date:  2020-06-29       Impact factor: 2.078

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.